AR and neoplasm: PSA, however, represents only a surrogate marker of tumor burden and utilizing LB to detect the emergence of certain genomic or transcriptomic aberrations (AR amplification, AR-V7, AR point mutations etc.)may signal the development of resistance earlier during treatment or at lower burdens of the resistant subpopulation and, thus, improve the performance of such adaptive models.